SCHEMBL5451568

SCHEMBL5451568

CO/N=C1\CCc2c(sc(NC(=O)C3CC3)c2C(N)=O)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.60
KDM4E B2RXH2 5/20 0.52
HSD17B10 Q99714 4/20 0.52
MAPT P10636 3/20 0.52
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
REV1 Q9UBZ9 2/20 0.48
DUSP3 P51452 1/20 0.47
PTPN5 P54829 1/20 0.47
PTPN11 Q06124 1/20 0.47
ALDH1A1 P00352 5/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 3/20 0.46
TSHR P16473 2/20 0.46
ALOX15 P16050 1/20 0.46
MAPK10 P53779 1/20 0.44
MDM2 Q00987 1/20 0.44
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CNR2 P34972 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451573 1.00 FLT3 (0.60) FLT3KDM4EHSD17B10MAPTMEN1
SCHEMBL5450827 0.89 FLT3 (0.65) FLT3KDM4EHSD17B10MAPTMEN1
SCHEMBL5450824 0.89 FLT3 (0.65) FLT3KDM4EHSD17B10MAPTMEN1
SCHEMBL5467190 0.86 FLT3 (0.65) FLT3KDM4EHSD17B10MAPTMEN1
SCHEMBL5467186 0.86 FLT3 (0.65) FLT3KDM4EHSD17B10MAPTMEN1
SCHEMBL5456323 0.81 FLT3 (0.51) FLT3KDM4EMAPTMEN1KMT2A
SCHEMBL5456329 0.81 FLT3 (0.51) FLT3KDM4EMAPTMEN1KMT2A
SCHEMBL5444887 0.80 FLT3 (0.70) FLT3KDM4EHSD17B10MAPTMEN1
SCHEMBL17018779 0.78 KCNH2 (0.57) FLT3KDM4EMAPTMEN1KMT2A
SCHEMBL17006374 0.78 KCNH2 (0.57) FLT3KDM4EMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885KDM4E 3417/4885HSD17B10 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.